Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 04 - 12 tags : Therapy save search
500GH, Senior Research Associate / Research Associate, Cancer Immunotherapy
Published: 2021-04-12 (Crawled : 00:00) - fatetherapeutics.com
FATE | $5.475 -2.93% 1.3M
|
Health Technology
|
| O: 0.01%
H: 6.6%
C: 5.19%
immunotherapy therapy cancer research
GT Biopharma Announces GTB-3550 TriKE™ Monotherapy Rescues and Restores NK Cell Immune Surveillance in Relapsed/Refractory AML and MDS Cancer Patients
Published: 2021-04-12 (Crawled : 14:00) - biospace.com/
GTBP | $3.85 1.32% 7.6K
|
Manufacturing
|
| O: -1.63%
H: 2.24%
C: 1.27%
biopharma therapy cancer aml
Bio-Path Holdings Presents BP1002 Data at 2021 American Association for Cancer Research Annual MeetingPreclinical Data Support BP1002 Combination Therapy in Venetoclax-resistant AML Patients
Published: 2021-04-12 (Crawled : 13:00) - biospace.com/
BPTH | $2.88 -2.04% 11K
|
Health Technology
|
| O: 0.29%
H: 0.29%
C: -8.6%
therapy cancer research aml
Genprex Collaborators Report Positive Preclinical Data for REQORSA™ Immunogene Therapy in Non-Small Cell Lung Cancer at the 2021 AACR Annual Meeting
Published: 2021-04-12 (Crawled : 13:00) - biospace.com/
GNPX | $2.29 -2.55% 7.8K
|
Health Technology
|
| O: 1.57%
H: 5.08%
C: -6.62%
lung cancer gene therapy positive therapy cancer collaboration preclinical pre-clinical
Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestasis
Published: 2021-04-12 (Crawled : 13:00) - biospace.com/
MIRM | $23.88 -0.13% 110K
|
Health Technology
|
| O: 1.15%
H: 1.03%
C: -1.25%
gene therapy therapy license gene therapies
Oncolytics Biotech® Presents Preclinical Data on Pelareorep-based Combination Therapies at the AACR Annual Meeting
Published: 2021-04-12 (Crawled : 12:00) - biospace.com/
ONCY | $1.05 -0.94% 240K
|
Health Technology
|
| O: 1.22%
H: 0.27%
C: -19.68%
biotech iot therapy preclinical pre-clinical
Taysha Gene Therapies Acquires Exclusive Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Program, Now Known as TSHA-120, for the Treatment of Giant Axonal Neuropathy, a Rare and Severe Neurodegenerative Disease
Published: 2021-04-12 (Crawled : 12:00) - biospace.com/
TSHA | $2.665 -9.35% 990K
|
Health Technology
|
| O: 10.05%
H: 15.78%
C: 7.2%
disease treatment neurodegenerative gene therapies gene therapy therapy aav9 rare
Intra-Cellular Therapies Presents Data on Antitumor Effects of Phosphodiesterase I Inhibition in a Preclinical Colorectal Cancer Model at the 2021 American Association for Cancer Research (AACR) Annual Meeting
Published: 2021-04-12 (Crawled : 12:00) - globenewswire.com
ITCI | $80.98 25.05% 5.7M
|
Health Technology
|
| O: 0.69%
H: 0.66%
C: -0.63%
cancer colorectal cancer research therapy preclinical pre-clinical
Affimed Highlights the Potential of its Innate Cell Engager AFM24 as EGFR-targeting Therapy for Solid Tumors as Monotherapy and in Combination with Adoptive NK Cell Transfer at AACR Virtual Annual Meeting I
Published: 2021-04-12 (Crawled : 11:00) - affimed.com
AFMD | $5.3 -3.46% 22K
|
Health Technology
|
| O: 3.8%
H: 0.1%
C: -4.55%
solid tumors potential therapy
Gainers vs Losers
| 54% | 46% |
Top 10 Gainers
WISA 4 | $7.86 349.14% 120M
|
Electronic Technology
TPET | $0.4951 114.24% 29M
|
n/a
JAGX | $0.1771 49.07% 540M
|
Health Technology
SXTC | $2.03 45.0% 27M
|
Health Technology
SPCB | $0.3888 40.87% 27M
|
Electronic Technology
DYNT | $0.52 40.39% 20M
|
Health Technology
SNGX | $0.54 39.86% 7.3M
|
Health Technology
BSGM | $1.53 39.09% 2.6M
|
Health Technology
MCBC | $13.74 38.37% 1.6M
|
Finance
PALI | $5.51 32.45% 28M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.